VCP-Targeted Therapy

VCP-Targeted Therapy

<div class="infobox infobox-treatment">
<div class="infobox-header">VCP-Targeted Therapy</div>
<div class="infobox-row">
<div class="infobox-label">Primary target</div>
<div class="infobox-value">VCP/p97 (Valosin-Containing Protein)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Therapeutic rationale</div>
<div class="infobox-value">Inhibit VCP ATPase activity to enhance autophagy, modulate ERAD, and clear toxic protein aggregates in neurodegenerative diseases</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Representative agents</div>
<div class="infobox-value">NMS-873, CB-5083, DBeQ, Roscovitine (Seliciclib)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Development status</div>
<div class="infobox-value">Preclinical with clinical-stage compounds in oncology repurposing</div>
</div>
</div>

Introduction

Valosin-containing protein (VCP), also known as p97, is a highly conserved AAA+ ATPase that plays critical roles in protein homeostasis, autophagy, and cellular stress responses. VCP mutations cause VCP-associated multisystem proteinopathy (MSP), characterized by inclusion body myopathy, Paget disease of bone, and frontotemporal dementia (IBMPFD). Additionally, VCP dysfunction is strongly implicated in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) pathogenesis. VCP-targeted therapy represents a promising therapeutic approach for these devastating neurodegenerative conditions. [@vcp2022]

Mechanism of Action

p97/VCP ATPase Inhibition

VCP-Targeted Therapy

<div class="infobox infobox-treatment">
<div class="infobox-header">VCP-Targeted Therapy</div>
<div class="infobox-row">
<div class="infobox-label">Primary target</div>
<div class="infobox-value">VCP/p97 (Valosin-Containing Protein)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Therapeutic rationale</div>
<div class="infobox-value">Inhibit VCP ATPase activity to enhance autophagy, modulate ERAD, and clear toxic protein aggregates in neurodegenerative diseases</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Representative agents</div>
<div class="infobox-value">NMS-873, CB-5083, DBeQ, Roscovitine (Seliciclib)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Development status</div>
<div class="infobox-value">Preclinical with clinical-stage compounds in oncology repurposing</div>
</div>
</div>

Introduction

Valosin-containing protein (VCP), also known as p97, is a highly conserved AAA+ ATPase that plays critical roles in protein homeostasis, autophagy, and cellular stress responses. VCP mutations cause VCP-associated multisystem proteinopathy (MSP), characterized by inclusion body myopathy, Paget disease of bone, and frontotemporal dementia (IBMPFD). Additionally, VCP dysfunction is strongly implicated in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) pathogenesis. VCP-targeted therapy represents a promising therapeutic approach for these devastating neurodegenerative conditions. [@vcp2022]

Mechanism of Action

p97/VCP ATPase Inhibition

VCP/p97 is a hexameric AAA+ ATPase that unfolds and translocates polyubiquitinated substrates through its central channel. Inhibiting VCP ATPase activity disrupts multiple cellular processes that become dysregulated in disease: [@vcpp2021]

• Proteasomal degradation: VCP extracts ubiquitinated proteins from the endoplasmic reticulum for proteasomal degradation via the ER-associated degradation (ERAD) pathway
• Autophagosome-lysosome fusion: VCP facilitates the recruitment of autophagic machinery to damaged organelles and protein aggregates
• DNA repair: VCP regulates DNA double-strand break repair through histone ubiquitination and repair factor recruitment
• Mitochondrial quality control: VCP-mediated mitophagy removes damaged mitochondria

Autophagosome-Lysosome Fusion Enhancement

VCP inhibition enhances autophagic flux by promoting autophagosome-lysosome fusion. In cells with VCP mutations or in neurodegenerative diseases with impaired autophagy, VCP inhibitors restore the ability of cells to clear toxic protein aggregates including: [@vcp2023]

• TDP-43 aggregates in ALS/FTD
• [Amyloid-beta](/proteins/amyloid-beta) plaques in Alzheimer's disease
• [Alpha-synuclein](/proteins/alpha-synuclein) Lewy bodies in Parkinson's disease
• [Huntingtin protein](/proteins/huntingtin) aggregates in Huntington's disease

ERAD Modulation

The ERAD pathway is crucial for degrading misfolded proteins from the endoplasmic reticulum. VCP inhibitors modulate ERAD activity, reducing the accumulation of toxic ER stress species that trigger apoptotic pathways in [neurons](/entities/neurons). [@erad2020]

Preclinical Evidence

VCP-Associated Inclusion Body Myopathy

In preclinical models of VCP-associated inclusion body myopathy (IBM), VCP inhibitors demonstrate: [@vcpassociated2021]

• Reduced cytoplasmic TDP-43 inclusions in muscle cells
• Improved mitochondrial function and reduced [ROS](/entities/reactive-oxygen-species) production
• Decreased muscle fiber degeneration
• Enhanced autophagic clearance of mutant VCP aggregates

ALS/FTD Models

In cellular and animal models of ALS and FTD: [@tdp2022]

• VCP knockdown or inhibition reduces TDP-43 aggregation
• VCP inhibitors improve survival of motor neurons in vitro
• In TDP-43 transgenic mice, VCP inhibition decreases TDP-43 pathology and improves behavioral outcomes
• Combination approaches with autophagy inducers show synergistic benefits

Amyotrophic Lateral Sclerosis

Multiple studies support VCP as a therapeutic target in ALS: [@vcp2023a]

• VCP mutations are found in familial ALS cases
• TDP-43 pathology in ALS involves VCP-mediated degradation pathways
• VCP inhibitors reduce excitotoxicity-induced motor neuron death
• Preclinical studies show improved neuromuscular function in ALS models

Clinical Trial Status

CDK5 Inhibitors with VCP Activity

Cyclin-dependent kinase 5 (CDK5) phosphorylates VCP and modulates its activity. [CDK5](/genes/cdk5) inhibitors with VCP-modulating properties are in development: [@cdk2021]

• Roscovitine (Seliciclib): Multi-CDK inhibitor that indirectly modulates VCP activity; completed Phase II trials for ALS with modest efficacy signals
• AT7519: [CDK5](/proteins/cdk5)/2/9 inhibitor in preclinical development for neurodegenerative diseases

Small Molecule VCP Inhibitors

Direct VCP inhibitors are in various stages of development: [@small2022]

• DBeQ: Early-stage VCP inhibitor demonstrating proof-of-concept in cellular models
• NMS-873: Potent VCP allosteric inhibitor showing efficacy in ALS/FTD models
• CB-5083: Clinical-stage VCP inhibitor (oncology); repurposing potential for neurodegeneration

Clinical Considerations

Current clinical development focuses on: [@clinical2023]

• Optimizing [blood-brain barrier](/entities/blood-brain-barrier) penetration
• Achieving sustained target engagement
• Balancing VCP inhibition with essential cellular functions
• Identifying patient populations with VCP dysfunction

Safety Profile

Known Adverse Effects

VCP inhibition can cause: [@vcp2021]

• Gastrointestinal effects (nausea, diarrhea)
• Transient liver enzyme elevations
• Potential impact on protein homeostasis in rapidly dividing cells

Therapeutic Window

The therapeutic window for VCP inhibition involves: [@therapeutic2022]

• Achieving sufficient CNS exposure for neuroprotective effects
• Avoiding complete VCP blockade (essential for cellular viability)
• Targeting disease-specific pathways at sub-lethal doses

Cross-Links to Related Pages

Related Genes and Proteins

• [VCP Gene](/genes/vcp) — Valosin Containing Protein
• [VCP/p97 Protein](/proteins/vcp-p97) — The therapeutic target

Related Diseases

• [VCP-Associated Multisystem Proteinopathy](/diseases/vcp-multisystem-proteinopathy) — Primary indication
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) — ALS
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia) — FTD

Related Mechanisms

• [Autophagy](/entities/autophagy) — Key mechanism of action
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy) — Key pathology
• [ER-Associated Degradation](/entities/erad) — ERAD pathway

Related Treatments

• [Autophagy Inducers in Neurodegeneration](/therapeutics/autophagy-inducers-neurodegeneration) — Complementary approach

Future Directions

VCP-targeted therapy represents a promising approach for neurodegenerative diseases characterized by impaired protein homeostasis. Key priorities include: [@future2024]

See Also

• VCP Protein (p97) - Valosin-Containing Protein
• [Inclusion Body Myopathy with Paget Disease of Bone and Frontotemporal Dementia (IBMPFD)](/diseases/frontotemporal-disease)
• [ALS (Amyotrophic Lateral Sclerosis)](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia (FTD)](/diseases/frontotemporal-dementia)
• ERAD (Endoplasmic Reticulum-Associated Degradation) - Mechanism
• Autophagy - Mechanism

External Links

• [VCP Mutations and Disease - Nature Reviews Neurology](https://pubmed.ncbi.nlm.nih.gov/32156290/)
• [IBMPFD Research Foundation](https://www.ibmpfd.org/)
• [ALS Association](https://www.als.org/)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [VCP-Mediated Autophagy Enhancement](/hypothesis/h-18a0fcc6) — <span style="color:#ffd54f;font-weight:600">0.54</span> · Target: VCP
• [VCP-Mediated Autophagy Enhancement](/hypothesis/h-18a0fcc6) — <span style="color:#ffd54f;font-weight:600">0.54</span> · Target: VCP
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;
• [Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;